Cancer located throughout the pancreas was ~3-fold more frequent in the DPC4- group (16.1%) than in the DPC4+ group (5.7%), while metastatic recurrence patterns were more dominant in the DPC4- group (77.0%) than in the DPC4+ group (44.3%). This evidence concerns the gene SMAD4 and cancer.